No connection

Search Results

ARCT vs KRRO

ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%
KRRO
Korro Bio, Inc.
BEARISH
Price
$12.68
Market Cap
$182.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARCT
--
KRRO
--
Forward P/E
ARCT
-1.61
KRRO
-1.67
P/B Ratio
ARCT
0.89
KRRO
2.32
P/S Ratio
ARCT
2.31
KRRO
28.61
EV/EBITDA
ARCT
0.22
KRRO
-1.82

Profitability

Gross Margin
ARCT
-36.79%
KRRO
0.0%
Operating Margin
ARCT
-435.06%
KRRO
-1229.33%
Profit Margin
ARCT
-80.19%
KRRO
0.0%
ROE
ARCT
-28.92%
KRRO
-110.7%
ROA
ARCT
-15.5%
KRRO
-32.14%

Growth

Revenue Growth
ARCT
-68.4%
KRRO
-43.1%
Earnings Growth
ARCT
--
KRRO
--

Financial Health

Debt/Equity
ARCT
0.12
KRRO
0.85
Current Ratio
ARCT
6.64
KRRO
6.9
Quick Ratio
ARCT
6.5
KRRO
6.38

Dividends

Dividend Yield
ARCT
--
KRRO
--
Payout Ratio
ARCT
0.0%
KRRO
0.0%

AI Verdict

ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
KRRO BEARISH

KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.

Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)

Compare Another Pair

ARCT vs KRRO: Head-to-Head Comparison

This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Korro Bio, Inc. (KRRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile